Date: February 11, 2026 Introduction In the first few weeks of 2026, a singular healthcare name has dominated the screens of institutional traders and retail investors alike: DaVita Inc. (NYSE: DVA). Once viewed with skepticism in late 2023 as the "Ozempic era" threatened to upend chronic kidney disease (CKD) management, DaVita has staged a remarkable [...]
Becton, Dickinson and Company (NYSE: BDX), widely known as BD, has long been a cornerstone of the global healthcare infrastructure. However, as of February 11, 2026, the company is making headlines not for its traditional stability, but for a radical transformation that has sent shockwaves through the market. Following the official completion of the multi-billion [...]
Today, February 9, 2026, marks a watershed moment for Becton, Dickinson and Company (NYSE: BDX). The medical technology giant, commonly known as BD, has officially closed its transformative $17.5 billion combination with Waters Corporation (NYSE: WAT), effectively spinning off its Biosciences and Diagnostic Solutions units to create a more streamlined "New BD." Simultaneously, the company [...]
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks.
But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
Shares of healthcare company Baxter International (NYSE:BAX)
fell 4.5% in the afternoon session after Barclays lowered its price target on the stock to $30 from $36, signaling a more cautious outlook on the company.
As of December 26, 2025, Baxter International Inc. (NYSE: BAX) stands at a pivotal crossroads in its nearly century-long history. Long considered a defensive "blue-chip" staple of the healthcare sector, Baxter spent much of the early 2020s grappling with the massive debt from its $10.5 billion acquisition of Hillrom, supply chain fragilities exposed by the [...]
Looking back on medical devices & supplies - diversified stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Baxter (NYSE:BAX) and its peers.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Shareholders of Baxter would probably like to forget the past six months even happened. The stock dropped 43.3% and now trades at $18.09. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Baxter has gotten torched over the last six months - since May 2025, its stock price has dropped 44.3% to $17.76 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Baxter’s third quarter results were met with a negative market reaction, as the company delivered top-line growth but missed Wall Street’s revenue expectations. Management attributed performance shortfalls primarily to ongoing challenges in its Infusion Therapies & Technologies division, which faced a continued pause on Novum IQ Large Volume pump shipments, and to softness in U.S. demand for IV solutions. CEO Andrew Hider candidly stated, “We are not satisfied with our current performance,” emphasizing that operational and segment-specific headwinds required immediate attention. The Healthcare Systems & Technologies segment, however, demonstrated improved performance during the quarter.
